Kuppalli Krutika, Brett-Major David M, Smith Tara C
Division of Infectious Diseases, Medical University of South Carolina, Charleston, South Carolina, USA.
Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Open Forum Infect Dis. 2021 Jan 4;8(2):ofaa658. doi: 10.1093/ofid/ofaa658. eCollection 2021 Feb.
In this perspective, we discuss the importance of developing a vaccine to help curb transmission of severe acute respiratory syndrome coronavirus 2. The question remains: Once a safe and effective vaccine is developed, will the public be willing to get it? We present information from one of the first tracking polls to assess public attitudes and perceptions toward a possible coronavirus disease 2019 vaccine that suggests public hesitancy over a potential vaccine, concern regarding accelerating clinical trials, and unease over the vaccine approval process. Public health experts, government officials, advocates, and others in the scientific community should respect the signals of hesitancy and communicate sensitivity, applying lessons not only to how we message, but also in how we build this urgently needed vaccine if we are to have successful uptake once available.
从这个角度来看，我们讨论了研发一种疫苗以帮助遏制严重急性呼吸综合征冠状病毒2传播的重要性。问题仍然存在：一旦研发出安全有效的疫苗，公众会愿意接种吗？我们展示了首批跟踪民意调查之一的信息，以评估公众对可能的2019冠状病毒病疫苗的态度和看法，这些信息表明公众对潜在疫苗存在犹豫、对加速临床试验感到担忧以及对疫苗审批过程感到不安。公共卫生专家、政府官员、倡导者以及科学界的其他人士应该尊重这些犹豫信号并进行敏感沟通，不仅要将这些经验应用于我们的宣传方式，还要应用于如果我们希望疫苗一旦可用就能成功推广，那么在研发这种急需的疫苗时的方式。
